Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy

Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01372891

Enrollment

400

Registered

2011-06-14

Start date

2010-04-30

Completion date

2014-12-31

Last updated

2011-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia

Keywords

Contrast Induced Nephropathy, percutaneous coronary interventions

Brief summary

The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.

Detailed description

Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* All patients \> 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.

Exclusion criteria

* The end-stage renal failure * The patients who are relieving dialysis

Design outcomes

Primary

Measure	Time frame	Description
increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline	3 days	samples will be collected at 24, 48 and 72 hours after PCI

Secondary

Measure	Time frame	Description
a 25% increase in SCr from baseline	3 days	samples will be collected at 24, 48 and 72 hours after PCI.

Countries

China

Contacts

Primary ContactLing Tao, M.D Ph.D

lingtao2006@gmail.com+86-15002955798

Outcome results